Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

• Status: Terminated
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ICON Bioscience Inc

Criteria

Inclusion Criteria:

• Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

Exclusion Criteria:

• Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.

• Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.

• Patients with any signs of intraocular inflammation in either eye at screening.

• Patients who have received any prior intravitreal injections in the study eye.